
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    ### Step-by-Step Analysis:<br><br>#### **1. List the Key Functional Markers**  <br>The markers provided are strongly associated with **cytotoxic immune cell function**, particularly **NK cells and cytotoxic T cells**. Key functional markers include:  <br>- **Cytotoxic granule proteins**:  <br>  - *GZMA, GZMB, GZMH, GZMK, GZMM* (Granzymes, essential for inducing apoptosis in target cells)  <br>  - *PRF1* (Perforin, pore-forming protein for granzyme delivery)  <br>  - *NKG7* (Activates cytotoxic granule polarization)  <br>- **Chemokines/Cytokines**:  <br>  - *CCL4, CCL4L2, CCL5* (Chemokines recruiting immune cells)  <br>  - *IFNG* (Interferon-Œ≥, key for antiviral/antitumor responses)  <br>- **Activation/Inhibitory receptors**:  <br>  - *KLRK1 (NKG2D)*, *KLRC2 (NKG2C)*, *KLRD1 (CD94)* (NK cell receptors)  <br>  - *TIGIT, LAG3, CD160* (Checkpoint inhibitors modulating cytotoxicity)  <br><br>#### **2. List the Key Cell Type Markers**  <br>The markers strongly suggest **cytotoxic lymphocytes**, with a mix of **NK cells and CD8+ T cells**:  <br>- **NK cell markers**:  <br>  - *KLRC2 (NKG2C)*, *KLRK1 (NKG2D)*, *KLRD1 (CD94)*, *CD160*  <br>  - *XCL1, XCL2* (Chemokines secreted by NK cells)  <br>- **CD8+ T cell markers**:  <br>  - *CD8A, CD8B* (Coreceptors for TCR-MHC-I interaction)  <br>  - *CD7, TRGC1, TRGC2* (Gamma-delta T cell markers, but also expressed in CD8+ T cells)  <br>- **Shared markers**:  <br>  - *NKG7, GZMs, PRF1, CST7* (Common in both NK and CD8+ T cells)  <br><br>#### **3. Cross-reference Known Databases**  <br>- **Human Cell Landscape (HCL) / CellMarker**:  <br>  - *KLRC2, KLRK1, KLRD1, XCL1* are classic **NK cell markers**.  <br>  - *CD8A/B, GZMK, GZMB* are enriched in **CD8+ effector/memory T cells**.  <br>  - *TRGC1/2* suggests a minor **Œ≥Œ¥ T cell** contribution.  <br>- **ImmGen / Tabula Sapiens**:  <br>  - *GZMH, GZMM, PRF1* are highly expressed in **NK cells and cytotoxic CD8+ T cells**.  <br>  - *CCL5, IFNG* are shared but more dominant in **NK cells**.  <br><br>#### **4. Determine the Most Probable General Cell Type**  <br>The cluster is **cytotoxic lymphocytes**, with a mix of **NK cells and CD8+ T cells**. Given the high expression of *KLRC2, KLRK1, XCL1/2*, and *NKG7*, **NK cells are the dominant population**, but there is likely a subset of **CD8+ cytotoxic T cells** (evidenced by *CD8A/B, GZMK*).  <br><br>#### **5. Identify the Top 3 Most Probable Sub Cell Types**  <br>Ranked by likelihood:  <br>1. **NK cells (CD56+)**  <br>   - *KLRC2, KLRK1, KLRD1, XCL1/2, NKG7, GZMH* are canonical NK markers.  <br>   - *CD160, TIGIT* suggest an activated/memory-like NK subset.  <br>2. **CD8+ cytotoxic T cells (effector/memory)**  <br>   - *CD8A/B, GZMK, GZMB, PRF1, CST7* are strong CD8+ T cell markers.  <br>   - *IFNG, CCL5* indicate an effector phenotype.  <br>3. **Œ≥Œ¥ T cells (minor subset)**  <br>   - *TRGC1/2* suggests a small Œ≥Œ¥ T cell contribution, but other markers are less specific.  <br><br>**Most likely subtype**: **Activated NK cells** (given dominance of *KLRC2, XCL1/2, NKG7* over *CD8A/B*).  <br><br>#### **6. Concise Summary**  <br>- **General cell type**: Cytotoxic lymphocytes (NK cells + CD8+ T cells).  <br>- **Dominant subtype**: **NK cells** (activated/memory-like, with *KLRC2/XCL1* signature).  <br>- **Secondary contributors**: CD8+ effector T cells and minor Œ≥Œ¥ T cells.  <br>- **Key markers**: *KLRC2, KLRK1, XCL1, NKG7* (NK); *CD8A/B, GZMK* (CD8+ T).  <br><br>**FINAL ANNOTATION COMPLETED**  <br>**Final call**: **NK cells (activated/memory-like) with a minor CD8+ T cell component**.
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    ### **Validation Report**  <br><br>#### **1. Marker Consistency Check**  <br>‚úÖ **All key markers used in the annotation are present in the provided marker list**:  <br>- **NK cell markers**: *KLRC2, KLRK1, KLRD1, XCL1, XCL2, NKG7, CD160, GZMH*  <br>- **CD8+ T cell markers**: *CD8A, CD8B, GZMK, GZMB, PRF1*  <br>- **Shared cytotoxic markers**: *GZMA, GZMB, GZMH, GZMK, PRF1, NKG7, CCL4, CCL5, IFNG*  <br><br>‚úÖ **No major discrepancies**‚Äîthe annotation aligns well with the provided markers.  <br><br>#### **2. Mixed Cell Type Consideration**  <br>‚ö†Ô∏è **Potential mixed population detected**:  <br>- The cluster shows **strong NK cell markers (KLRC2, XCL1, NKG7)** alongside **CD8+ T cell markers (CD8A/B, GZMK)**.  <br>- **Œ≥Œ¥ T cell markers (TRGC1/2)** are present but weak, suggesting a minor subset.  <br><br>üîç **Recommendation**:  <br>- If possible, **subcluster to resolve NK vs. CD8+ T cells** (e.g., using *CD8A/B* vs. *KLRC2/XCL1*).  <br>- If subclustering is not feasible, the current annotation (**NK cells with a minor CD8+ T cell component**) is reasonable but should be noted as a **heterogeneous population**.  <br><br>#### **3. Final Validation Decision**  <br>‚úÖ **VALIDATION PASSED**  <br>- The annotation is **biologically plausible** and supported by the marker list.  <br>- The **mixed population warning** is noted but does not invalidate the result.  <br><br>**Feedback for Improvement**:  <br>- If further resolution is needed, consider **re-clustering with NK vs. CD8+ T cell markers** to confirm proportions.  <br>- Alternatively, label as **"Cytotoxic Lymphocytes (NK/CD8+ T mix)"** for transparency.  <br><br>**Final Call**: **VALIDATION PASSED (with note on potential heterogeneity).**
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">NK cells (activated/memory-like)</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>NK cells (CD56+)</li><li>CD8+ cytotoxic T cells (effector/memory)</li><li>Œ≥Œ¥ T cells (minor subset)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>CD8+ T cells</li><li>Œ≥Œ¥ T cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">92</div>
                        <div class="scoring-content">
                            The annotation results demonstrate a strong understanding of cytotoxic lymphocyte biology, accurately identifying the dominant NK cell population and acknowledging the presence of CD8+ T cells and a minor Œ≥Œ¥ T cell subset. Here‚Äôs a detailed evaluation:<br><br>### **Strengths**:<br>1. **Scientific Accuracy**:  <br>   - The annotation correctly identifies **NK cells** as the dominant population, supported by canonical markers like *KLRC2 (NKG2C)*, *KLRK1 (NKG2D)*, *XCL1/2*, and *NKG7*.  <br>   - The inclusion of **CD8+ T cells** is justified by *CD8A/B*, *GZMK*, and *GZMB*, while *TRGC1/2* hints at a minor Œ≥Œ¥ T cell contribution.  <br>   - The distinction between **activated/memory-like NK cells** (via *TIGIT*, *CD160*) and **effector CD8+ T cells** (via *IFNG*, *CCL5*) is well-reasoned.  <br><br>2. **Balanced Marker Usage**:  <br>   - The analysis does not over-rely on a single marker but integrates multiple lines of evidence (cytotoxic granules, chemokines, receptors). For example:  <br>     - *GZMA/B/H/K/M* and *PRF1* collectively support cytotoxic function.  <br>     - *KLRC2* and *CD8A/B* are weighted appropriately to distinguish NK vs. T cells.  <br><br>3. **Comprehensive View**:  <br>   - The annotation captures heterogeneity, noting the **mixed population** of NK and CD8+ T cells and suggesting subclustering for resolution.  <br>   - Databases (HCL, Tabula Sapiens) are referenced to validate marker specificity.  <br><br>### **Weaknesses**:  <br>1. **Minor Oversights**:  <br>   - *LAG3* and *TIGIT* are highlighted as checkpoint inhibitors but could be further contextualized as markers of **exhaustion** in chronic settings (e.g., tumor microenvironment).  <br>   - *IL21R* (associated with follicular helper T cells) is not discussed, though its low relevance here is understandable.  <br><br>2. **Œ≥Œ¥ T Cell Ambiguity**:  <br>   - While *TRGC1/2* suggests Œ≥Œ¥ T cells, other Œ≥Œ¥-specific markers (e.g., *TRDV2*) are absent. The annotation could explicitly state that Œ≥Œ¥ T cells are **possible but not definitive**.  <br><br>3. **Rank of Markers**:  <br>   - The analysis does not explicitly prioritize markers by expression rank (e.g., *KLRC2* vs. *CD8A*), though the conclusion implicitly reflects this.  <br><br>### **Overall**:  <br>The annotation is **highly accurate** and provides a **nuanced view** of the data, balancing dominant and minor populations. The minor weaknesses do not detract significantly from the overall correctness.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    